Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 9
Submit an article Journal homepage
143
Views
0
CrossRef citations to date
0
Altmetric
Preliminary Communication

Rapid Deaminator Status is Associated With Poor Clinical Outcome in Pancreatic Cancer Patients Treated with a Gemcitabine-Based Regimen

Cindy Serdjebi1 Transfer Oncology Laboratory, Nord University Hospital of Marseille, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France;2 Clinical Pharmacokinetics Laboratory, La Timone University Hospital of Marseille, Inserm S_911 CRO2, Aix-Marseille University, Marseille, FranceView further author information
,
Jean-François Seitz3 Digestive Oncology Unit, La Timone University Hospital of Marseille, APHM, FranceView further author information
,
Joseph Ciccolini1 Transfer Oncology Laboratory, Nord University Hospital of Marseille, Inserm S_911 CRO2, Aix-Marseille University, Marseille, France;2 Clinical Pharmacokinetics Laboratory, La Timone University Hospital of Marseille, Inserm S_911 CRO2, Aix-Marseille University, Marseille, FranceCorrespondence[email protected]
View further author information
,
Muriel Duluc3 Digestive Oncology Unit, La Timone University Hospital of Marseille, APHM, FranceView further author information
,
Emmanuelle Norguet3 Digestive Oncology Unit, La Timone University Hospital of Marseille, APHM, FranceView further author information
,
Frédéric Fina1 Transfer Oncology Laboratory, Nord University Hospital of Marseille, Inserm S_911 CRO2, Aix-Marseille University, Marseille, FranceView further author information
,
Bruno Lacarelle2 Clinical Pharmacokinetics Laboratory, La Timone University Hospital of Marseille, Inserm S_911 CRO2, Aix-Marseille University, Marseille, FranceView further author information
,
L‘Houcine Ouafik1 Transfer Oncology Laboratory, Nord University Hospital of Marseille, Inserm S_911 CRO2, Aix-Marseille University, Marseille, FranceView further author information
&
Laetitia Dahan3 Digestive Oncology Unit, La Timone University Hospital of Marseille, APHM, FranceView further author information
 show all
Pages 1047-1051 | Published online: 09 Jul 2013

References

  • Ciccolini J , MercierC, DahanL, AndreN. Integrating pharmacogenetics into gemcitabine dosing – time for a change? Nat. Rev. Clin. Oncol.8(7) , 439–444 (2011).
  • Tibaldi C , GiovannettiE, VasileE et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14(6) , 1797–1803 (2008).
  • Yonemori K , UenoH, OkusakaT et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin. Cancer Res. 11(7) , 2620–2624 (2005).
  • Caronia D , MartinM, SastreJ et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand–foot syndrome. Clin. Cancer Res. 17(7) , 2006–2013 (2011).
  • Ciccolini J , EvrardA, LacarelleB. A CDD polymorphism as predictor of capecitabine-induced hand–foot syndrome – letter. Clin. Cancer Res.18(1) , 317 (2012).
  • Ciccolini J , EvrardA, M‘BatchiL et al. CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. Pharmacogenomics 13(4) , 393–397 (2012).
  • Ciccolini J , DahanL, AndreN et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J. Clin. Oncol. 28(1) , 160–165 (2010).
  • Mercier C , DahanL, OuafikL, AndreN, CiccoliniJ. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur. J. Clin. Pharmacol.66(9) , 959–960 (2010).
  • Giovannetti E , TibaldiC, FalconeA, DanesiR, PetersGJ. Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. J. Clin. Oncol.28(14) , e221–e222; author reply e223–e225 (2010).
  • Mercier C , RaynalC, DahanL et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet. Genomics 17(10) , 841–844 (2007).
  • Sugiyama E , KaniwaN, KimSR et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25(1) , 32–42 (2007).
  • Andre F , McShaneLM, MichielsS et al. Biomarker studies: a call for a comprehensive biomarker study registry. Nat. Rev. Clin. Oncol. 8(3) , 171–176 (2011).
  • O‘Reilly EM . Adjuvant therapy for pancreas adenocarcinoma. J. Surg. Oncol.107(1) , 78–85 (2013).
  • von Hoff DD , RamanathanRK, BoradMJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II trial. J. Clin. Oncol. 29(34) , 4548–4554 (2011).
  • Dahan L , CiccoliniJ, EvrardA et al. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications. J. Clin. Oncol. 30(4) , e41–e44 (2012).
  • Tibaldi C , GiovannettiE, TiseoM et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Ann. Oncol. 23(3) , 670–677 (2012).
  • Bengala C , GuarneriV, GiovannettiE et al. Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br. J. Cancer 93(1) , 35–40 (2005).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.